160 unknown. 160 Phase 2, 43 Phase 1, 8 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 160 | Unknown 160 |
| Phase 1 | 43 | Unknown 43 |
| Phase 3 | 8 | Unknown 8 |
Follow Neoplasm Metastasis: new trials by email Literature Review of Neoplasm Metastasis trials Research Report on Neoplasm Metastasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer Eribulin, Bevacizumab - Breast Neoplasms, Neoplasm Metastasis | Phase 2 | Unknown | Wang Jiayu | 60 | 2024-08-01 | 2024-08-06 |
| Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer Liposomal irinotecan, Capecitabine, Bevacizumab - Colorectal Cancer | Phase 2 | Unknown | Harbin Medical University | 63 | 2024-04-01 | 2024-01-18 |
| TSN222 in Subjects With Advanced Solid Tumors or Lymphomas Phase I dose escalation, Phase II-HNSCC, Phase II-Advanced melanoma - Has a Pathologically Documented Unresectable Locally Advanced or Metastatic Solid Tumor or Lymphoma | Phase 1 / Phase 2 | Unknown | Tyligand Bioscience (Shanghai) Limited | 162 | 2023-07-26 | 2024-07-29 |
| Decitabine and Anti-PD-1 in R/R DLBCL Low-Dose Decitabine plus anti-PD-1 - Diffuse Large B Cell Lymphoma, Relapse/Recurrence | Phase 2 | Unknown | Chinese PLA General Hospital | 20 | 2023-05-15 | 2023-05-09 |
| The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment Penpulimab - Pheochromocytoma, Metastatic, Pheochromocytoma Malignant | Phase 2 | Unknown | Peking Union Medical College Hospital | 5 | 2023-04-01 | 2023-06-02 |
| A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer bevacizumab, erlotinib - Solid Tumors, Advanced Solid Tumors | Phase 2 | Unknown | Asan Medical Center | 32 | 2023-01-02 | 2023-06-15 |
| PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors. Hypofractionated radiotherapy, PD-L1 inhibitor, GM-CSF - Metastatic Solid Tumor | Phase 2 | Unknown | Second Affiliated Hospital of Soochow University | 56 | 2022-09-01 | 2022-09-07 |
| Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Mitomycin, Lobaplatin - Colorectal Cancer, Chemotherapy Effect | Phase 2 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 201 | 2022-09-01 | 2022-02-21 |
| A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer chidamide, camrelizumab, carboplatin - Triple-negative Breast Cancer | Phase 2 | Unknown | Fudan University | 70 | 2022-07-10 | 2022-06-30 |
| A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma HLX301 - Advanced Tumors, Lymphoma | Phase 1 / Phase 2 | Unknown | Shanghai Henlius Biotech | 30 | 2022-06-20 | 2023-08-08 |
| Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02 SHR-1316, SHR6390, Nab paclitaxel - Breast Cancer, Metastatic Cancer | Phase 2 | Unknown | Fudan University | 338 | 2022-06-06 | 2024-02-08 |
| Evaluation of Tumour Growth and Oncological Treatment in Patients With CRLM Using Zebra Fish Embryo Model Chemotherapy drug - Colorectal Cancer Metastatic, Tumour Metastasis | Phase 1 / Phase 2 | Unknown | University Hospital, Linkoeping | 40 | 2022-05-17 | 2023-12-01 |
| A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors JBI-802 - Locally Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 / Phase 2 | Unknown | Jubilant Therapeutics Inc. | 126 | 2022-04-08 | 2023-06-15 |
| Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma Envafolimab, Oxaliplatin, S1 - Metastatic or Recurrent Gastric Adenocarcinoma | Phase 2 | Unknown | Liangjun Zhu M.M. | 38 | 2022-03-01 | 2024-01-05 |
| Sintilimab Combined With Chemotherapy and SBRT in Limited Metastatic Head and Neck Squamous Cell Carcinoma (LM-HNSCC) Sintilimab, SBRT, Platinum based chemotherapy - Head and Neck Squamous Cell Carcinoma, Metastases | Phase 2 | Unknown | Jun-Lin Yi, MD | 50 | 2021-12-01 | 2021-11-29 |
| A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies CN202 - Locally Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 / Phase 2 | Unknown | Curon Biopharmaceutical (Australia) Co Pty Ltd | 164 | 2021-10-22 | 2021-08-31 |
| EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers EMB-01 - Neoplasms, Neoplasm Metastasis | Phase 1 / Phase 2 | Unknown | Shanghai EpimAb Biotherapeutics Co., Ltd. | 152 | 2021-10-21 | 2024-08-26 |
| Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas nal-irinotecan (nal-iri) (Onyvide), oxaliplatin (ox), 5-fluouracil (5-FU), folinic acid (FA) - Pancreatic Cancer, Metastasis | Phase 2 | Unknown | University of Cologne | 150 | 2021-10-10 | 2024-01-12 |
| Phase I/II Study of AloCelyvir in Patients With Metastatic Uveal Melanoma AloCelyvir - Uveal Melanoma, Metastatic | Phase 1 / Phase 2 | Unknown | José María Piulats Rodríguez | 16 | 2021-10-01 | 2021-09-17 |
| A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma stereotactic body radiotherapy, Immunotherapy - Uveal Melanoma | Phase 2 | Unknown | California Pacific Medical Center Research Institute | 40 | 2021-09-20 | 2022-12-06 |
Showing 20 of 160. Sign in to see all of them.
Breast Neoplasms (24) · Colorectal Neoplasms (17) · Stomach Neoplasms (14) · Neoplasms (13) · Melanoma (10) · Pancreatic Neoplasms (10) · Recurrence (10) · Brain Neoplasms (7) · Prostatic Neoplasms (7) · Carcinoma, Hepatocellular (5) · Rectal Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (4) · Carcinoma, Renal Cell (4) · Colonic Neoplasms (4)
Neoplastic Processes (160) · Pathologic Processes (160) · Pathological Conditions, Signs and Symptoms (160) · Neoplasms (147) · Neoplasms by Site (111) · Digestive System Diseases (50) · Digestive System Neoplasms (49) · Neoplasms by Histologic Type (48) · Gastrointestinal Diseases (36) · Skin Diseases (36) · Skin and Connective Tissue Diseases (36) · Gastrointestinal Neoplasms (35) · Breast Diseases (27) · Neoplasms, Glandular and Epithelial (26) · Carcinoma (20)
Capecitabine (14) · Oxaliplatin (11) · Cisplatin (10) · Bevacizumab (9) · Fluorouracil (8) · Gemcitabine (8) · Cetuximab (6) · Docetaxel (6) · Irinotecan (6) · Paclitaxel (6) · Cyclophosphamide (5) · Ipilimumab (5) · Leucovorin (5) · Nivolumab (5) · Sunitinib (5)
Chinese PLA General Hospital (5) · Fudan University (5) · National Cancer Center, Korea (5) · Aronex Pharmaceuticals (3) · Chinese Academy of Medical Sciences (3) · Consorzio Oncotech (3) · Asan Medical Center (2) · GERCOR - Multidisciplinary Oncology Cooperative Group (2) · Goshen Health System (2) · Hadassah Medical Organization (2) · NeuroVita Clinic (2) · Shanghai EpimAb Biotherapeutics Co., Ltd. (2) · Shanghai Junshi Bioscience Co., Ltd. (2) · Sung Yong Oh (2) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (2)
China (44) · United States (28) · South Korea (15) · Germany (8) · Italy (8) · Netherlands (8) · France (7) · Spain (7) · Australia (5) · Belgium (4) · Canada (4) · Croatia (3) · Denmark (3) · Israel (3) · Russia (3)
Andrey S. Bryukhovetskiy, MD (2) · Grazia Arpino, MD (2) · Kaixiong Tao, Professor (2) · Kenneth L. Pennington, MD (2) · Qamar Khan, MD (2) · Sook Ryun Park, M.D (2) · Sung Yong Oh, MD (2) · Zhi-Ming Shao (2) · Alfredo Budillon, M.D (1) · Alwin Kraemer, Prof. Dr. (1) · Anatoliy V. Voronin (1) · Anli Tong (1) · Anne Demols, MD, PhD (1)
PMID 25303679, PMID 25789053, PMID 32306237, PMID 10091726, PMID 10555755, PMID 11123390, PMID 11813623, PMID 14963856, PMID 15042609, PMID 15215160, PMID 15313917, PMID 15681523, PMID 15755984, PMID 16172161, PMID 16172168, PMID 17016557, PMID 17543307, PMID 17647245, PMID 18268188, PMID 18443902, PMID 18854571, PMID 18981929, PMID 19091394, PMID 19097774, PMID 19220526, PMID 19289619, PMID 19308068, PMID 19349550, PMID 19519435, PMID 19720913, PMID 20299316, PMID 20450446, PMID 20498403, PMID 20679609, PMID 21376385, PMID 21383283, PMID 21502559, PMID 21990397, PMID 22056152, PMID 22287157, PMID 22823994, PMID 22831982, PMID 22866066, PMID 23168366, PMID 24290503, PMID 24821581, PMID 24950987, PMID 25146529, PMID 25202099, PMID 25217422
2017 (3), 2015 (2), 2019 (2), 2014 (1), 2016 (1), P30CA060553 (1)